Results 171 to 180 of about 26,268,552 (306)

The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia. [PDF]

Transl Cancer Res
Szymczyk A, Hus I.
europepmc   +1 more source

Infliximab Monotherapy as First-Line Treatment for Hepatic, Splenic, and Pulmonary Sarcoidosis in a Patient With High Cardiometabolic Risk. [PDF]

Cureus
Coimbra M, Saca C, Carvalho MC, Neves M, Delgado Alves J.   +4 more
europepmc   +1 more source

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study

, 2015
Norbert Marschner,1 Dirk Arnold,2 Erik Engel,3 Ulrich Hutzschenreuter,4 Jacqueline Rauh,5 Werner Freier,6 Holger Hartmann,7 Melanie Frank,8 Martina Jänicke7 On behalf of the TKK Registry Group 1Praxis für Interdisziplinäre Onkologie und ...
Marschner N, Engel E, Jänicke M, Rauh J, Arnold D, Frank M, Freier W, Hutzschenreuter U, Hartmann H   +8 more
core  

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer. [PDF]

Oncologist
Meeks M, Iranmanesh Y, Song H, Blackford AL, Rasouli A, Baras A, Denmeade SR, Markowski MC, Paller CJ, Carducci MA, Antonarakis ES, Eisenberger MA, Marshall CH.   +12 more
europepmc   +1 more source

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

, 2009
Serena Ricciardi1, Silverio Tomao2, Filippo de Marinis11Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo-Forlanini High Specialization Hospitals, Rome, Italy; 2Sperimental Medicine Department, Rome, ItalyAbstract: Pemetrexed is a new ...
Silverio Tomao, Serena Ricciardi, Filippo de Marinis   +2 more
core  

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

Molecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault, Capucine Heraud, Mélissa Correia de Oliveira, Véronique Neaud, Valérie Valesco, Valérie Prouzet‐Mauleon, Béatrice Turcq, Jean‐William Dupuy, Anne‐Aurélie Raymond, Sabrina Croce, Frédéric Saltel, Valérie Lagrée, Violaine Moreau   +12 more
wiley   +1 more source

Prognostic impact of baseline blood biomarkers in SCLC first-line treatment. [PDF]

Ther Adv Med Oncol
Wang Y, Ren M, Liu J, Xiang Z, Ding H, Xie J, Ding N, Yang Y.   +7 more
europepmc   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial). [PDF]

Br J Haematol
Gallamini A, Viviani S, Rapezzi D, Patti C, Feugier P, Rambaldi A, Bijou F, Borra A, Borel C, Pace-Loscos T, Schiappa R, Chauvie S, Debaigt C, Guidetti A, Humbert O, De Colella JS.   +15 more
europepmc   +1 more source